Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors

Journal of Thoracic Oncology

Volumn 10, Issue 9, 2015, Pages 1341-1348

  Pilotto, Sara ^a   Sperduti, Isabella ^b   Novello, Silvia ^c   Peretti, Umberto ^a   Milella, Michele ^b   Facciolo, Francesco ^b   Vari, Sabrina ^b   Leuzzi, Giovanni ^b   Vavalà, Tiziana ^c   Marchetti, Antonio ^d   Mucilli, Felice ^d   Crinò, Lucio ^e   Puma, Francesco ^e   Kinspergher, Stefania ^a   Santo, Antonio ^a   Carbognin, Luisa ^a   Brunelli, Matteo ^f   Chilosi, Marco ^f   Scarpa, Aldo ^f   Tortora, Giampaolo ^a   Bria, Emiolio ^a   more..

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF VERONA   (Italy)

Author keywords

Clinicopathological predictors; Prognosis; Prognostic model; Squamous lung cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SQUAMOUS CELL LUNG CARCINOMA; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84940107590     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000628     Document Type: Article

References (39)

1. Maemondo M, Inoue A, Kobayashi K, North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 362 2380 2388
2. Mitsudomi T, Morita S, Yatabe Y, West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010 11 121 128
3. Rosell R, Carcereny E, Gervais R, Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012 13 239 246
4. Shaw AT, Kim DW, Nakagawa K, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 368 2385 2394
5. Goldstraw P, Crowley J, Chansky K, International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007 2 706 714
6. Warth A, Muley T, Meister M, The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012 30 1438 1446
7. Yoshizawa A, Sumiyoshi S, Sonobe M, Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 2013 8 52 61
8. Kadota K, Nitadori J, Woo KM, Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 2014 9 1126 1139
9. Tsutani Y, Miyata Y, Mimura T, Prognostic impact of lymphatic invasion for pathological stage I squamous cell carcinoma of the lung. Gen Thorac Cardiovasc Surg 2015 63 153 158
10. Wei S, Asamura H, Kawachi R, Sakurai H, Watanabe S, Which is the better prognostic factor for resected non-small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification? J Thorac Oncol 2011 6 310 318
11. Cancer Genome Atlas Research N Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012 489 519 525
12. Iasonos A, Schrag D, Raj GV, Panageas KS, How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 2008 26 1364 1370
13. Alonzo TA, Standards for reporting prognostic tumor marker studies. J Clin Oncol 2005 23 9053 9054
14. Simon RM, Paik S, Hayes DF, Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009 101 1446 1452
15. Shuster JJ, Median follow-up in clinical trials. J Clin Oncol 1991 9 191 192
16. Hess KR, Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995 14 1707 1723
17. Pencina MJ, D'Agostino RB, Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004 23 2109 2123
18. Bria E, Milella M, Sperduti I, A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. Lung Cancer 2009 66 365 371
19. Hanley JA, McNeil BJ, The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982 143 29 36
20. Di Maio M, Lama N, Morabito A, Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer 2010 46 735 743
21. Bria E, De Manzoni G, Beghelli S, A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol 2013 24 693 701
22. Sauerbrei W, Schumacher M, A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 1992 11 2093 2109
23. Efficace F, Bottomley A, Smit EF, EORTC Lung Cancer Group and Quality of Life Unit Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 2006 17 1698 1704
24. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA, Regression modelling strategies for improved prognostic prediction. Stat Med 1984 3 143 152
25. Schemper M, Smith TL, A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996 17 343 346
26. Greiner M, Pfeiffer D, Smith RD, Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev Vet Med 2000 45 23 41
27. Agarwal M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP, Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer 2010 68 398 402
28. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P, International Staging Committee and Participating Institutions The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009 4 792 801
29. th Edition. J Thorac Oncol 2008 3 457 466
30. Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL, Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 2003 21 1029 1034
31. Osarogiagbon RU, Ogbata O, Yu X, Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer. Ann Thorac Surg 2014 97 385 393
32. Saji H, Tsuboi M, Yoshida K, Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol 2011 6 1865 1871
33. Masuda R, Kijima H, Imamura N, Tumor budding is a significant indicator of a poor prognosis in lung squamous cell carcinoma patients. Mol Med Rep 2012 6 937 943
34. Yilmaz A, Duyar SS, Cakir E, Clinical impact of visceral pleural, lymphovascular and perineural invasion in completely resected non-small cell lung cancer. Eur J Cardiothorac Surg 2011 40 664 670
35. Kinoshita T, Ohtsuka T, Hato T, Prognostic factors based on clinicopathological data among the patients with resected peripheral squamous cell carcinomas of the lung. J Thorac Oncol 2014 9 1779 1787
36. Goya T, Asamura H, Yoshimura H, Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005 50 227 234
37. Nakazato Y, Maeshima AM, Ishikawa Y, Interobserver agreement in the nuclear grading of primary pulmonary adenocarcinoma. J Thorac Oncol 2013 8 736 743
38. Warth A, Stenzinger A, von Brünneck AC, Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. Eur Respir J 2012 40 1221 1227
39. Liang W, Zhang L, Jiang G, Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol 2015 33 861 869